Chronic Kidney Disease Clinical Trial
Official title:
Sit Less, Interact, Move More (SLIMM) Intervention Pilot Study
In the past two decades, the prevalence of obesity in the US has increased from 23.2% to 32.9%. This epidemic is fueling the Chronic Kidney Disease (CKD) epidemic. This likely is the major challenge facing the nephrology community in the next decade and beyond. This pilot study is designed to test the feasibility of the Sit Less, Interact, Move More (SLIMM) intervention and to determine its preliminary impact on light physical activity (PA) levels. Increasing light PA may have significant impact on both obesity and slowing the progression of CDK.
More than one-third of U.S. adults (35.7%) are obese (body mass index (BMI) > 30 kg/m2). In
2008, medical costs associated with obesity were estimated at $147 billion. Furthermore,
there is a graded association of BMI and the risk of end stage renal disease (ESRD). Indeed,
increasing prevalence of CKD in the US population is partly explained by increasing BMI.
Hence, as a public health policy, it is imperative that obesity be targeted in order to
decrease the morbidity, mortality and the healthcare costs burden associated with CKD and
ESRD.
Physical inactivity plays a major role in obesity. Volitional exercise (VE), which includes
moderate to vigorous physical activities (MVPA) such as sports and fitness-related
activities, and non-volitional exercise, which includes low to light intensity physical
activity (PA) such as activities of daily living, fidgeting, spontaneous muscle contraction,
and maintaining posture in non-recumbent positions, represent two different ends of the PA
spectrum. The current national recommendations are focused on MVPA (30 minutes of moderate
PA five times a week or 25 minutes of vigorous activities three times a week). However, the
relative importance of low and light activities and MVPA has not been established. As
described in the preliminary data, the analyses of objectively measured PA in National
Health And Nutrition Examination Survey (NHANES) suggest that a larger amount of light
intensity PA is strongly associated with lower odds of proteinuria, lower odds of CKD and a
lower hazard of death at any given level of MVPA. Furthermore, there appears to be a
threshold effect for MVPA with mortality that plateaus at about half of the currently
recommended levels of MVPA. Since physical function in the CKD population is low, 30 minutes
of moderate PA five times a week or 25 minutes of vigorous activities three times a week
might induce fatigue and paradoxically reduce light intensity PA. On the other hand, a lower
target of MVPA might improve adherence with MVPA as well as not decrease light PA. This
pilot intervention study will test the efficacy, feasibility and tolerability of the SLIMM
intervention. The results of this intervention will be later used to determine if targeting
obesity via the SLIMM intervention will slow kidney disease progression.
DESIGN:
This is a pilot intervention study that will examine the feasibility of and adherence to the
SLIMM intervention to increase levels of light physical activity
Baseline visit: Baseline PA data will be collected by accelerometer in the week following
the screening visit. Participants will be instructed on the importance of physical activity,
the recommendations of 150 min/wk of moderate PA, or 75 min/wk of vigorous PA, and be
provided with examples of physical activities.
SLIMM Intervention: The goal of the SLIMM intervention is to increase the time spent on
light activities (Light physical activity is defined as 500-2019 counts/minute). This
intervention will only be completed by individuals in the CKD and non-CKD groups. At week 6
of the intervention participants will be instructed to perform 5 minutes of light activity
for each 25 minutes of sitting time. At week 12, participants will be instructed to further
increase their light activity to a goal of 10 minutes for each 20 minute of sitting time.
Thus, the goal is to replace total sedentary time by increase in light activities by 15% in
6 weeks and 33% by the end of the intervention.
All participants will undergo standardized training on the SLIMM intervention by trained
study personnel at the 6 week visit. Participants will initially be asked to perform 5
minutes of light activity for every 25 minutes spent seated. At the week 12 visit,
participants will be asked to further increase their activity, by performing 10 minutes of
light activity for every 20 minutes spent seated.
Training will be provided in one to one sessions and reinforced at the following visits.
Accelerometry data and paper PA diary data collected during the week before the baseline
visit will be reviewed with the participant to provide feedback and used for devising a
customized plan on increasing light activity. Examples of how to increase light activities
within their natural, free-living environment will be provided. For instance, if the
majority of their day is spent working at a desk, they will be encouraged to stand and/or
walk for 5 minutes for every 25 minutes spent sedentary during weeks 6-12, and 10 minutes of
light activity for every 20 minutes spent sedentary for weeks 12-18. Participants will be
asked to stand and/or walk during commercial breaks when they are watching television.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
Terminated |
NCT04043026 -
The Effects of Renal Function and Atrial Fibrillation on Lipoproteins and Clot Structure/Function
|
||
Completed |
NCT05318014 -
Low-protein Formula Supplements in Chronic Kidney Disease
|
N/A | |
Active, not recruiting |
NCT06071065 -
Clinical Pharmacist Intervention on Medication Adherence and Clinical Outcomes in Chronic Kidney Disease Patients
|
N/A | |
Completed |
NCT02878317 -
Skin Autofluorescence as a Risk Marker in People Receiving Dialysis.
|
||
Not yet recruiting |
NCT06039254 -
Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function
|
Phase 1 | |
Recruiting |
NCT03160326 -
The QUALITY Vets Project: Muscle Quality and Kidney Disease
|
||
Completed |
NCT02836574 -
A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease
|
Phase 2 | |
Completed |
NCT02896309 -
The Effect of Correction of Metabolic Acidosis in CKD on Intrarenal RAS Activity
|
N/A | |
Completed |
NCT02756520 -
Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-024-CNI)
|
||
Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
Completed |
NCT02875886 -
DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease
|
Phase 4 | |
Withdrawn |
NCT02885545 -
The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial
|
Phase 4 | |
Active, not recruiting |
NCT02483039 -
Nephrologist Follow-up Versus Usual Care After an Acute Kidney Injury Hospitalization
|
N/A | |
Terminated |
NCT02543177 -
Optimised Procedure in Patients With NSTEMI and CKD
|
N/A | |
Completed |
NCT02992548 -
Effect of Pravastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease
|
Phase 4 | |
Completed |
NCT02369549 -
Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease
|
Phase 3 | |
Recruiting |
NCT02205944 -
Impact of Presurgical Exercise on Hemodialysis Fistula Outcomes
|
N/A | |
Active, not recruiting |
NCT02231138 -
Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease
|
Phase 4 |